What Are the Requirements for Risk Management Documentation in South Korean Medical Device Registration?

For medical device registration in South Korea, the risk management file must reflect the product's intended use, risk classification, applicable regulatory pathway and existing documentation base, and its conclusions must be consistent with the technical file, quality system evidence, labeling and clinical evidence. Manufacturers should complete a documentation gap assessment before formal submission so that unclear classification, evidence coverage or authorization arrangements do not extend the registration timeline.

Published: 15 July 2026, 17:57  |  Updated: 15 July 2026, 17:57

This article reviews the questions that companies need to prioritize in real projects, covering international medical device registration, documentation preparation, compliance pathways and post-market maintenance.

Content Structure

• Key Summary
• Applicable Scenarios and Core Questions
• Registration Determination Logic
• Documentation and Evidence
• Common Mistakes
• Company Preparation Checklist
• AIMEILI Perspective
• Frequently Asked Follow-Up Questions
• Continue Reading
• Applicability Boundaries

Key Summary

On the question of what the risk management documentation requirements are for medical device registration in South Korea, companies should first confirm the target country, the product risk class, the applicable regulatory pathway and the existing documentation base, and then assess the technical file, quality system, labeling and instructions for use, local agent, clinical evidence and post-market maintenance requirements. AIMEILI recommends completing a documentation gap assessment before formal submission, in order to avoid extended project timelines caused by unclear classification, documentation or authorization arrangements.

For Chinese medical device manufacturers, the more reliable approach is to first perform product classification and a documentation gap assessment, and then determine whether NMPA, CE, FDA, ISO 13485 or other market documentation can be reused. Registration in a target market typically affects the technical file, authorized representative, importer cooperation, label language, quality system certification and subsequent change maintenance at the same time. If a project is driven only by the question of which documents to submit, rework or deficiency letters are likely to arise in model coverage, evidence chain consistency, labeling claims and certificate control. AIMEILI recommends placing this question within a broader GHWP member state and multi-country market access strategy, using one reusable core technical file to support localization in different markets rather than re-creating documentation country by country.

This content is compiled from the AIMEILI regulatory practice question bank, the medical device international registration knowledge base and publicly available regulatory information. Specific projects should be based on the latest requirements of the target country's regulatory authority and the product documentation base.

Applicable Scenarios and Core Questions

Companies searching for the requirements for risk management documentation in South Korean medical device registration are usually not looking for a conceptual explanation. They want to determine whether their existing documentation can support a submission in the target market, whether a local agent or authorized representative is required, why timelines are extended, and which issues could affect the launch plan. Behind this question are often product classification, registration pathway, evidence chain, label localization and post-market maintenance responsibilities.

If a company plans to enter several GHWP member states or markets in Southeast Asia, the Middle East and Latin America at the same time, answering the process for one country alone is not enough. A more valuable approach is to first build reusable versions of the core technical file, quality system evidence, performance verification, clinical evidence and labeling, and then localize them according to each country's regulatory requirements.

Registration Determination Logic

Companies should first confirm the intended purpose, mechanism of action, use scenario, body contact, duration of use, sterility, whether the device is active, and whether it contains software or has IVD characteristics, and then determine the risk class and submission pathway. If the pathway is determined incorrectly, the subsequent translation, notarization, authorization, testing and supplementary documentation will all move in the wrong direction.

For a target market project, the applicant entity and local responsibility boundaries must also be confirmed: who holds the certificate, who is responsible for regulatory communication, who handles import and post-market incidents, who triggers changes, and who maintains renewal documentation. If these issues are left vague in commercial contracts, they can easily affect market control later.

Documentation and Evidence

Typical documentation includes:

• Product description, model and specification matrix, and intended use
• Risk classification rationale
• ISO 13485 or applicable quality system evidence
• Technical file and performance verification reports
• Risk management file
• Clinical evaluation or clinical evidence
• Labeling and instructions for use
• Authorization documents and existing registration certificates
• Manufacturer declarations and post-market surveillance documentation

The key to documentation quality is not volume but consistency. Labeling claims, the models covered by test reports, the scope of clinical evidence, risk management conclusions, label warnings and the information in the registration application form must support one another. Regulatory authorities focus on whether the device is safe, effective and traceable for its intended use, not on how many documents have been uploaded.

Common Mistakes

• Treating registration as a simple document submission without first clarifying product classification, evidence coverage and local responsibility relationships.
• Submitting translated NMPA documentation directly without restructuring the evidence according to the target market pathway.
• Listing too many models and specifications while test reports, clinical evidence or labeling coverage are insufficient.
• Selecting a local agent purely on the basis of a sales partnership, without defining regulatory responsibility, certificate control and post-market maintenance obligations.
• Inconsistency between labels, instructions for use, promotional materials and registration claims, leading to deficiency letters or post-market compliance risk.
• Failing to plan multi-country documentation reuse in advance, resulting in duplicated preparation for each country and inflated cost and timelines.

Company Preparation Checklist

Before starting a project, companies are advised to use an internal checklist to confirm their documentation base, so that critical evidence gaps are not discovered only after submission.

• Compile the target product list, model and specification matrix, and intended use statements.
• Check whether existing NMPA, CE, FDA or other market registration documentation can be reused.
• Prepare the ISO 13485 certificate, test reports, risk management documentation, clinical evaluation and English instructions for use.
• Confirm the responsibilities, fees, certificate control and exit mechanisms of the local agent or authorized representative.
• Establish a target-country gap assessment table specifying what requires additional testing, translation, notarization or supplementary declarations.

AIMEILI Perspective

AIMEILI recommends that companies treat target market registration not as a one-off document submission but as an overseas market access program. For companies preparing to enter multiple countries, building a clear core technical file and evidence matrix first and then converting it to national requirements is usually faster, more stable and better for subsequent changes and renewals than filling documentation gaps country by country.

From a project management perspective, three items should be controlled early: first, product classification and pathway determination; second, consistency of the documentation evidence chain; third, the regulatory responsibility boundaries of local partners. If these three items are unclear, the project may still go through repeated rounds at the deficiency response, agent communication and post-market maintenance stages, even if the documentation appears substantial.

Frequently Asked Follow-Up Questions

Can domestic documentation be used directly for target market registration?

Domestic documentation can serve as a basis, but it usually cannot be submitted as it stands. Companies need to adjust the documentation structure, language, labeling, authorization documents and evidence chain according to local regulatory requirements.

When is the best time to start a gap assessment?

It is recommended to start immediately after the target market and product list are confirmed. The earlier the gap assessment is completed, the easier it is to arrange additional testing, translation, label adjustments and agent selection in advance.

Why does the choice of local agent affect registration quality?

A local agent usually participates in registration communication, changes, renewals and post-market incident handling. Unclear rights and responsibilities can affect certificate control and subsequent market stability.

Project Execution Recommendations

When executing this type of registration project, companies should maintain a project ledger that manages the product list, models and specifications, registration pathway, documentation owners, translation status, testing status, local agent communication records and expected submission dates in a single table. This makes documentation gaps visible in time and helps management judge whether the project will affect the launch plan.

For companies that already have registrations in several countries, an evidence reuse matrix should also be established, specifying which documents can serve as core evidence and which must be reissued or supplemented according to national requirements. In particular, labeling and instructions for use, clinical evaluation, risk management, performance verification and quality system certificates must remain version-consistent.

• Confirm the target market and product list.
• Complete risk classification and pathway determination.
• Establish a documentation gap assessment table.
• Define the local agent and certificate control.
• Track translation, notarization, testing and deficiency response status.
• Arrange post-market maintenance responsibilities in advance.

Quality System and Evidence Consistency

From a registration review perspective, quality system documentation is not an isolated certificate. Regulatory authorities typically check whether the manufacturer name, manufacturing address, product scope, certificate validity, applicable standards and technical file are consistent with one another. If the scope of the ISO 13485 certificate does not match the products being registered, or if the manufacturing address, models and specifications or instructions for use version do not match the test reports, additional clarification may be required even when a large volume of documentation has been prepared.

Companies should establish an evidence consistency checklist before submission, mapping the product name, models and specifications, intended use, applicable standards, test report numbers, clinical evaluation conclusions, risk management version, labeling and instructions for use version, and quality system certificate item by item. This appears basic, but it can significantly reduce the probability of deficiency letters, particularly for projects registered simultaneously in several GHWP member states or with multiple product series.

Localization and Agent Responsibilities

Target market registration projects usually involve arrangements with a local agent, authorized representative, importer or registration holder. Companies need to confirm in advance whether the local partner only submits documentation or also assumes regulatory communication, certificate maintenance, post-market incident reporting, change applications and renewal reminders. Different responsibility boundaries directly affect certificate control and subsequent market stability.

Labeling, instructions for use and authorization documents also cannot simply be translated. Companies should verify local language requirements, the boundaries of product claims, warnings, storage and transport conditions, UDI or traceability requirements, importer information, authorized representative information and after-sales contact details. For companies that already hold CE, FDA, NMPA or other market documentation, the focus of localization is converting reusable evidence into a submission structure acceptable in the target country, rather than writing a separate set of isolated documents.

Post-Market Maintenance and Long-Term Planning

Registration is not the end of compliance work. Companies also need to maintain certificate validity, change records, distributor authorizations, complaint handling, adverse event reporting, recall procedures, label versions and regulatory update records. Many companies invest heavily in obtaining the certificate but neglect post-market maintenance, and then find that the certificate no longer matches actual market sales once a manufacturing address change, model extension, instructions for use update or agent replacement occurs.

AIMEILI recommends managing this question within an annual international registration plan: first define target market priorities, then build reusable documentation packages and country gap lists, and finally schedule submission, deficiency response, post-market maintenance and renewal milestones. The value is not only improved efficiency in a single country; more importantly, it allows companies to build a repeatable overseas compliance capability and reduces the cost of starting documentation from scratch each time they enter a new market.

Continue Reading

Previous: How Should Multiple Models Be Grouped for Medical Device Registration in South Korea?

Next: How Should Performance Verification Documentation Be Prepared for Medical Device Registration in South Korea?

Recommended reading

• How Should a Local Agent Be Selected for Medical Device Registration in Brazil?
• How Are Authorized Representative Responsibilities Divided for Medical Device Registration in Brazil?
• Why Do Medical Device Registration Timelines in Brazil Get Extended?
• What Are the Common Reasons for Deficiency Letters in Medical Device Registration in Brazil?
• How Is Post-Market Surveillance Conducted for Medical Device Registration in Brazil?
• When Must a Registration Change Be Filed for Medical Device Registration in Brazil?

Return to the FAQ Center  |  News & Updates  |  Contact AIMEILI

Content Review and Applicability Boundaries

Content author: AIMEILI Regulatory Editorial Team

Professional review: AIMEILI Medical Device International Registration Project Team

Source principle: priority is given to official regulatory authorities, international organizations, standards organizations and publicly available regulatory materials; industry media and project experience are used only as supporting judgment.

Applicability boundary: This article is intended for preliminary understanding, documentation preparation and project planning. It does not replace the formal requirements of the target country's regulatory authority, testing conclusions or legal advice.